<DOC>
	<DOC>NCT00709475</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin detemir under normal clinical practice conditions in the Gulf countries</brief_summary>
	<brief_title>Observational Safety Study in Subjects Using LevemirÂ® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newlydiagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician Subjects who are unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for the final visit; Subjects currently being treated with insulin detemir; Subjects who previously enrolled in this study or studies related to NovoMix 30; Subjects with a hypersensitivity to insulin detemir or to any of the excipients; Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 8 months.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>